Page last updated: 2024-08-25

bexarotene and Adverse Drug Event

bexarotene has been researched along with Adverse Drug Event in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Aiba, S; Amagai, R; Fujimura, T; Fujisawa, Y; Fukushima, S; Kambayashi, Y; Miyashita, A; Ogata, D; Sato, Y; Shimauchi, T; Tanita, K	1
Altmann, DR; Brown, JWL; Chandran, S; Chard, DT; Coles, AJ; Connick, P; Cunniffe, NG; Ffrench-Constant, C; Flynn, PD; Franklin, RJM; Gandini Wheeler-Kingshott, CAM; Georgieva, Z; Jones, JL; Kanber, B; MacManus, D; Michell, AW; Moran, C; Needham, E; Overell, J; Pearson, OR; Prados, F; Rog, D; Samson, RS; Stutters, J	1

Trials

1 trial(s) available for bexarotene and Adverse Drug Event

Article	Year
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. The Lancet. Neurology, 2021, Volume: 20, Issue:9 Topics: Adult; Bexarotene; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Evoked Potentials, Visual; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Remyelination; Retinoid X Receptors	2021

Article

Year

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

The Lancet. Neurology, 2021, Volume: 20, Issue:9

Topics: Adult; Bexarotene; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Evoked Potentials, Visual; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Remyelination; Retinoid X Receptors

2021

Other Studies

3 other study(ies) available for bexarotene and Adverse Drug Event

Article	Year
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, 2011, Volume: 7, Issue:12 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. The Journal of dermatology, 2020, Volume: 47, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Chemoradiotherapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Japan; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Severity of Illness Index; Skin Neoplasms; Ultraviolet Therapy	2020